 Cystic Fibrosis Transmembrane Conductance Regulator
"Cystic Fibrosis Transmembrane Conductance Regulator" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A chloride channel that regulates secretion in many exocrine tissues. Abnormalities in the CFTR gene have been shown to cause cystic fibrosis. (Hum Genet 1994;93(4):364-8)
| Descriptor ID |
D019005
|
| MeSH Number(s) |
D12.776.157.530.100.304.500 D12.776.157.530.400.175.125 D12.776.157.530.450.074.500.500.500.500 D12.776.543.550.450.175.125 D12.776.543.585.100.304.500 D12.776.543.585.400.175.125 D12.776.543.585.450.074.500.500.500.500
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Cystic Fibrosis Transmembrane Conductance Regulator".
Below are MeSH descriptors whose meaning is more specific than "Cystic Fibrosis Transmembrane Conductance Regulator".
This graph shows the total number of publications written about "Cystic Fibrosis Transmembrane Conductance Regulator" by people in this website by year, and whether "Cystic Fibrosis Transmembrane Conductance Regulator" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 1 | 0 | 1 | | 2000 | 1 | 0 | 1 | | 2001 | 1 | 1 | 2 | | 2002 | 3 | 1 | 4 | | 2003 | 1 | 2 | 3 | | 2004 | 5 | 3 | 8 | | 2005 | 1 | 1 | 2 | | 2006 | 4 | 3 | 7 | | 2007 | 5 | 3 | 8 | | 2008 | 3 | 3 | 6 | | 2009 | 7 | 2 | 9 | | 2010 | 3 | 1 | 4 | | 2011 | 3 | 3 | 6 | | 2012 | 2 | 1 | 3 | | 2013 | 4 | 0 | 4 | | 2014 | 4 | 2 | 6 | | 2015 | 6 | 1 | 7 | | 2016 | 4 | 6 | 10 | | 2017 | 4 | 4 | 8 | | 2018 | 9 | 2 | 11 | | 2019 | 7 | 8 | 15 | | 2020 | 10 | 6 | 16 | | 2021 | 12 | 9 | 21 | | 2022 | 11 | 15 | 26 | | 2023 | 1 | 22 | 23 | | 2024 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Cystic Fibrosis Transmembrane Conductance Regulator" by people in Profiles.
-
Ramsey B, Correll CU, DeMaso DR, McKone E, Tullis E, Taylor-Cousar JL, Chu C, Volkova N, Ahluwalia N, Waltz D, Tian S, Mall MA. Elexacaftor/Tezacaftor/Ivacaftor Treatment and Depression-related Events. Am J Respir Crit Care Med. 2024 02 01; 209(3):299-306.
-
Daines CL, Tullis E, Costa S, Linnemann RW, Mall MA, McKone EF, Polineni D, Quon BS, Ringshausen FC, Rowe SM, Selvadurai H, Taylor-Cousar JL, Withers NJ, Ahluwalia N, Moskowitz SM, Prieto-Centurion V, Tan YV, Tian S, Weinstock T, Xuan F, Zhang Y, Ramsey B, Griese M. Long-term safety and efficacy of elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis and at least one F508del allele: 144-week interim results from a 192-week open-label extension study. Eur Respir J. 2023 12; 62(6).
-
Patil R, Magaret AS, Jain R, Taylor-Cousar J, Hughan KS, Kazmerski TM. Factors associated with pubertal growth outcomes in cystic fibrosis: Early Growth and Puberty in CF. J Cyst Fibros. 2024 May; 23(3):538-544.
-
Taylor-Cousar JL, Janney R, Middleton PG, Jain R, Nightingale J, West NE, Shteinberg M, Velez D, Kazmerski TM. A provider survey assessing fetal impact of CFTR modulator use in males with CF during assisted and unassisted reproduction and partner pregnancy. J Cyst Fibros. 2024 May; 23(3):412-416.
-
Hisert KB, Vladar EK. Cystic Fibrosis Airways: Does Disease Stem from Faulty Stem Cells? Am J Respir Crit Care Med. 2023 11 01; 208(9):913-914.
-
Yuan F, Gasser GN, Lemire E, Montoro DT, Jagadeesh K, Zhang Y, Duan Y, Ievlev V, Wells KL, Rotti PG, Shahin W, Winter M, Rosen BH, Evans I, Cai Q, Yu M, Walsh SA, Acevedo MR, Pandya DN, Akurathi V, Dick DW, Wadas TJ, Joo NS, Wine JJ, Birket S, Fernandez CM, Leung HM, Tearney GJ, Verkman AS, Haggie PM, Scott K, Bartels D, Meyerholz DK, Rowe SM, Liu X, Yan Z, Haber AL, Sun X, Engelhardt JF. Transgenic ferret models define pulmonary ionocyte diversity and function. Nature. 2023 Sep; 621(7980):857-867.
-
Taylor-Cousar JL, Boyd AC, Alton EWFW, Polineni D. Genetic therapies in cystic fibrosis. Curr Opin Pulm Med. 2023 11 01; 29(6):615-620.
-
Taylor-Cousar JL, Robinson PD, Shteinberg M, Downey DG. CFTR modulator therapy: transforming the landscape of clinical care in cystic fibrosis. Lancet. 2023 09 30; 402(10408):1171-1184.
-
Hisert KB, Birket SE, Clancy JP, Downey DG, Engelhardt JF, Fajac I, Gray RD, Lachowicz-Scroggins ME, Mayer-Hamblett N, Thibodeau P, Tuggle KL, Wainwright CE, De Boeck K. Understanding and addressing the needs of people with cystic fibrosis in the era of CFTR modulator therapy. Lancet Respir Med. 2023 10; 11(10):916-931.
-
Mayer-Hamblett N, Clancy JP, Jain R, Donaldson SH, Fajac I, Goss CH, Polineni D, Ratjen F, Quon BS, Zemanick ET, Bell SC, Davies JC, Jain M, Konstan MW, Kerper NR, LaRosa T, Mall MA, McKone E, Pearson K, Pilewski JM, Quittell L, Rayment JH, Rowe SM, Taylor-Cousar JL, Retsch-Bogart G, Downey DG. Advancing the pipeline of cystic fibrosis clinical trials: a new roadmap with a global trial network perspective. Lancet Respir Med. 2023 10; 11(10):932-944.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|